TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05810779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic surface exercise
Description: Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk targeted training
Description: trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks
Study: NCT05977725

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Doppler Ultrasound
Description: Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Doppler Ultrasound
Description: Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)
Study: NCT06150144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SURGERY
Description: Total excision of the lesion
Study: NCT06326970

Intervention type: DIAGNOSTIC_TEST
Intervention: 99mTc-FAPI SPECT imaging
Description: 99mTc radionuclide is labeled to a HYINC-FAPI-04 probe as a tracer. SPECT imaging was performed 2 hours after 99mTc-FAPI intravenous injection into the subject, and image processing and quantitative analysis were performed using the Q.Volumetrix MI System software package.
Study: NCT04044534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Subjects in this arm will receive intranasal insulin (80 IU per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects in this arm will receive placebo.
Study: NCT05197101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon catheter combined with oxytocin induction
Description: Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
Study: NCT05767541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercises
Description: Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
Study: NCT06498375

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance
Description: Fluid distribution measured by bioelectrical impedance Bodystat Multiscan 5000 Bodystat Ltd, Isle of Man, British Isles

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance
Description: Fluid distribution measured by bioelectrical impedance Bodystat Multiscan 5000 Bodystat Ltd, Isle of Man, British Isles
Study: NCT04820478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Hydroxybutyrate Ester (KetoneAid KE4)
Description: see arm/group description

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: see arm/group description
Study: NCT05074745

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA POCT vs RT-PCR
Description: 3 swabs taken, buccal for RT-PCR and ELISA POCT, nasopharyngeal for RT-PCR
Study: NCT05841121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Antenatal dexamethasone will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
Study: NCT06068491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vet-CALD
Description: Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
Study: NCT06560827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT011 CAR-GPC3 T Cells Injection
Description: The dose selection for this trial was mainly based on the preliminary safety and efficacy results of CT011-HCC-01 trial in subjects with advanced HCC, in which 3 and 5 subjects in the 2.5 × 108 cell and 5.0 × 108 cell dose groups, respectively, completed a single infusion of CT011. The results showed that the two dose groups of CT011 were generally well tolerated in HCC subjects who failed to standard treatment, with controllable safety, and showed preliminary anti-tumor efficacy.
Study: NCT05047536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-261
Description: KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
Study: NCT06016738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palazestrant
Description: Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Participants will be treated with letrozole once daily on a 4 week (28 day) cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
Study: NCT06563505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given by IV
Study: NCT06131463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) feature in smart watches
Description: A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
Study: NCT05187637

Intervention type: DRUG
Intervention: intravenous iron
Description: One dose of intravenous iron carboxymaltose calculated according to ganzoni's formula. If after thirty days of the first dose, a second dose of 500mg will be administered if the patient continues to meet the inclusion criteria.
Study: NCT06386042

Intervention type: OTHER
Intervention: no intervention, observational study
Description: no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).

Intervention type: OTHER
Intervention: no intervention, observational study
Description: no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).

Intervention type: OTHER
Intervention: no intervention, observational study
Description: no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).
Study: NCT05198310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-404
Description: Humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-404
Description: Humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-404
Description: Humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-404
Description: Humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-404
Description: Humanized monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06644612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Weight Mesh
Description: Participants will undergo abdominal hernia repair using light-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy Weight Mesh
Description: Participants will undergo abdominal hernia repair using heavy-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
Study: NCT06097806

Intervention type: OTHER
Intervention: low and high flow
Description: low and high flow anesthesia are both being used. The effects of different gas flows will be evaluated.

Intervention type: OTHER
Intervention: low and high flow
Description: low and high flow anesthesia are both being used. The effects of different gas flows will be evaluated.
Study: NCT04986527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube suction
Description: The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube suction
Description: The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
Study: NCT05450068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan's Mobilization with movement
Description: The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan's Mobilization with movement
Description: The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
Study: NCT06203665

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver
Description: The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
Study: NCT05374993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3TBA
Description: Induce third molar tooth bud agenesis
Study: NCT05558670

Intervention type: OTHER
Intervention: PET-fMRI-EEG
Description: Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap

Intervention type: OTHER
Intervention: PET-fMRI-EEG
Description: Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap

Intervention type: OTHER
Intervention: PET-fMRI-EEG
Description: Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap

Intervention type: OTHER
Intervention: PET-fMRI-EEG
Description: Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap
Study: NCT06328621

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo low-dose CT
Study: NCT06002061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaResp MAPR System
Description: Baseline measurements will be taken while the subject is awake. Genioglossus activity with maximal tongue protrusion will be measured as well as the response to 1 to 2 pressure routines. Once the subject is sleeping, the operator will observe the PSG recording and determine sleep stage and respiratory phase (inspiration, expiration, between breaths). Test routines will be performed for each sleep stage and each respiratory phase. If the operator notices an apnea occurring, one of the routines will be applied. When all manual tests are complete, an automatic mode will be engaged for the remainder of the night. During this mode, a previously developed and trialled AI model will be used to predict if an obstructive apnea is upcoming. The operator will input which routine to test, and the routine will be automatically applied when a prediction occurs. There will be a minimum of 60 seconds between pressure routine applications.
Study: NCT06328621

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT05255484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: An Anti-PD-1 Antibody
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: An Anti-PD-1 Antibody
Description: Administered intravenously
Study: NCT06196047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg loading dose of cilostazol administered within 24 hours of first-ever ischemic stroke followed by 100 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
Study: NCT05813847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Local infiltration of study drug
Study: NCT06328621

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT05618847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella,ACBTS
Description: Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACBTs
Description: Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACBTs
Description: Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
Study: NCT05835193

Intervention type: OTHER
Intervention: Diagnostic Test: Distance Visual Acuity Examination
Description: Best spectacle-corrected distance visual acuity and reading capacity of pre-school students in Alexandroupolis, Greece will be examined via a web-based digital visual acuity chart
Study: NCT05813847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: local anaesthetic injection
Description: Local infiltration of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Local infiltration of study drug
Study: NCT06557421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: complete discontinuation of Venetoclax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: complete discontinuation of Azacitidine
Study: NCT05194982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study: NCT06556329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot (Intervention)
Description: The research team will bring a socially assistive, artificially-enhanced robot during intravenous insertion procedures.
Study: NCT05163691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH001 Placebo administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH001 Placebo administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GH001 Placebo administered via inhalation
Study: NCT05033600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S.C.I.O.
Description: The devices read, emit and entrain Electromagnetic waves of the body.
Study: NCT05450068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spencer's muscle energy technique
Description: Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spencer's muscle energy technique
Description: Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
Study: NCT05850377

Intervention type: DRUG
Intervention: 5-Aminolevulinic Acid (5-ALA) Gliolan®
Description: Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.

Intervention type: PROCEDURE
Intervention: Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)
Description: During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.
Study: NCT05025540

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic imaging
Description: Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
Study: NCT05858333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended culture for Group 2: (day 3-5 group)
Description: To investigate thawing day three embryos and culturing them to be transferred as blastocyst that will improve pregnancy rate when compared to transfer thawed frozen blastocyst.